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Endothelial dysfunction and reduced nitric oxide in resistance
arteries in autosomal-dominant polycystic kidney disease.
Background. Patients with autosomal-dominant polycystic
kidney disease (ADPKD) have defective endothelium-depen-
dent relaxation (EDR). We investigated the relationship be-
tween endothelial dysfunction and nitric oxide generation in
hypertension and chronic renal insufficiency (CRI) in ADPKD.
Methods. We contrasted acetylcholine (ACh)-induced EDR,
3-morphollinosydnonimine (SIN-1)-induced endothelium-inde-
pendent relaxation (EIDR) and constitutive nitric oxide syn-
thase (cNOS) activity in subcutaneous resistance vessels and
plasma levels and excretion of NO2 /NO3 (NOX) in normal,
control (N  10) patients with ADPKD or essential hyperten-
sion.
Results. EDR was decreased significantly in normotensive
ADPKD (N  9), but more severely in hypertensive ADPKD
(N  6), or those with CRI (N  5) and in essential hyperten-
sion (N  9). The increases in EDR with l-arginine and de-
creases with LG-nitro-l-arginine methyl ester (L-NAME) were
lost in all groups of patients with ADPKD and in essential
hypertension except for a modest effect of L-NAME in normo-
tensive ADPKD. EIDR was unimpaired throughout. Vascular
cNOS activity and renal NOX excretion were reduced pro-
foundly in patients with all categories of ADPKD and espe-
cially in those with hypertension.
Conclusion. EDR in resistance vessels from patients with
ADPKD is impaired even in the absence of hypertension or
CRI, but becomes more marked as hypertension develops.
Patients with ADPKD have defective nitric oxide generation
from diminished cNOS activity. Endothelial dysfunction and
impaired cNOS activity in ADPKD may predispose to hyper-
tension whose occurrence is accompanied by a further sharp
deterioration in EDR.
Autosomal-dominant polycystic kidney disease
(ADPKD) is a relatively common genetic disorder. Al-
though the kidneys are the major site of clinical disease,
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it is a multisystem disorder affecting the liver, blood
vessels, and heart valves. Large vessels in ADPKD may
show vascular ectasia and aneurysms as well as aortic root
dilatation [1]. Development of hypertension in ADPKD
is succeeded by the onset of chronic renal insufficiency
(CRI). The causes of this early rise in blood pressure
remain controversial [2].
Endothelium-dependent relaxation of arteries can be
induced in vitro by acetylcholine (ACh), which functions
as an activator of nitric oxide synthase (NOS) by increas-
ing intracellular calcium [3]. An impaired relaxation re-
sponse of resistance vessels to ACh has been proposed
to contribute to vascular disease in essential hyperten-
sion and diabetes mellitus [4–7]. Endothelium-derived
nitric oxide plays an important role in maintaining ho-
meostasis of the cardiovascular system [8, 9]. Nitric oxide
is generated from the metabolic conversion of l-arginine
into l-citrulline by the activity of NOS. The major vascu-
lar isoform of constitutive NOS (cNOS) is endothelial
NOS (eNOS), which is implicated in endothelium-depen-
dent relaxation with ACh [3]. eNOS knockout mice have
an impaired endothelium-dependent relaxation and mild
hypertension [10]. These observations have led to the
concept that resistance vessels in vivo are maintained
in a constant state of vasodilatation by endogenously
released nitric oxide.
An impaired relaxation response of resistance vessels
to ACh may contribute to vascular disease in essential
hypertension and CRI. Recently, we have demonstrated
that endothelium-dependent relaxation to ACh and its re-
sponse to the NOS inhibitor, LG-nitro-l-arginine methyl
ester (L-NAME), are impaired in mesenteric vessels of a
rat model of polycystic kidney disease (PKD) (Han:SPRD)
[11] and in patients with ADPKD [12].
Since both hypertension and CRI can cause endothe-
lial dysfunction, the first aim of this study is to dissociate
the effects of endothelial dysfunction due to ADPKD
from the associated hypertension or CRI. We contrasted
endothelial function in groups of age-matched normo-
tensive control subjects, ADPKD without hypertension
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or CRI, ADPKD with hypertension, ADPKD with hy-
pertension and CRI, and in a further group of patients
with essential hypertension. Care was taken to character-
ize hypertension quantitatively from ambulatory 24-hour
blood pressure monitoring, and renal function from the
plasma clearance of [51Cr]-ethylenediaminetetraacetic
acid (EDTA). Endothelial dysfunction could represent
defects in endothelium-derived relaxation factor (EDRF)
nitric oxide, in responsiveness to nitric oxide in NOS activ-
ity, or in endothelium-derived hyperpolarization factor
(EDHF). Therefore, the second aim was to investigate
the mechanism of endothelial dysfunction in subcutane-
ous vessels dissected from patients with ADPKD. We as-
sessed the role of nitric oxide from the effects of l-arginine
or L-NAME on ACh-induced vasorelaxation, from mea-
surements of NOS activity and from 24-hour excretion
of the nitric oxide metabolite, NO2 /NO3 (NOX).
METHODS
Patients
The protocol was approved by the Medical Ethics
Committee, Copenhagen County, Denmark. All individ-
uals gave written informed consent before entering the
study. Ten healthy control subjects, nine normotensive
ADPKD patients, six hypertensive ADPKD patients
without CRI, five hypertensive ADPKD patients with
CRI, and nine patients with essential hypertension were
studied. The patients’ ages were 23 to 60 years. All sub-
jects were Caucasians and without hypercholesterol-
emia. All patients with ADPKD were diagnosed by renal
ultrasound showing five or more renal cysts distributed
in both kidneys. Most patients had a positive family
history of ADPKD. The diagnosis of essential hyperten-
sion was established by the presence of hypertension
and the absence of clinical and laboratory evidence of
secondary hypertension or diabetes mellitus and normal
serum electrolytes, creatinine, and urinalysis. Inclusion
criteria for the normotensive ADPKD patients were that
patients consistently had a systolic blood pressure 140
mm Hg and a diastolic blood pressure 90 mm Hg.
Patients were considered hypertensive when their clinic
systolic blood pressure was consistently 140 mm Hg
or diastolic blood pressure was 90 mm Hg or when
they were taking antihypertensive drugs. No antihyper-
tensive or other drugs were taken by the patients with
normotensive ADPKD or the control subjects. All pa-
tients with hypertensive ADPKD and those with essen-
tial hypertension were treated with two or more different
antihypertensive drugs [angiotensin-converting enzyme
(ACE) inhibitors, angiotensin receptor blockers, beta
blockers, alpha-beta blockers, calcium antagonists, or
diuretics]. Vessels for study were harvested as described
below 24 hours or more after the most recent drug intake.
Plasma creatinine was normal (68 to 105mol/L) in eight
of nine normotensive ADPKD patients, all hypertensive
ADPKD patients without CRI, and all patients with
essential hypertension. A Takeda 2420 monitor (Takeda,
Tokyo, Japan) was used to measure 24-hour ambulatory
blood pressure. Glomerular filtration rate (GFR) was
calculated from the 4-hour, one-sample plasma clearance
method using [51Cr]-EDTA [13]. All measurements were
completed within 1 week of the subcutaneous fat biopsy
described below.
Preparation of small subcutaneous vessels
A biopsy of subcutaneous fat of 1.0  0.5  0.5 cm
was obtained from the gluteal region under local anes-
thesia with 1% lidocaine hydrochloride and placed im-
mediately in cold physiologic salt solution (PSS) (sodium
chloride 118 mmol/L, sodium bicarbonate 25 mmol/L,
potassium chloride 4.5 mmol/L, calcium chloride 2.5
mmol/L, magnesium sulfate 1.0 mmol/L, and glucose 6.0
mmol/L). Using a dissecting microscope (Olympus SN450,
Copenhagen, Denmark), two segments of small arteries
(about 2 mm in length with a mean diameter of 200 to
300 m) were cleaned and frozen in liquid nitrogen for
subsequent measurement of NOS activity. Another two
segments of the same artery were prepared for functional
studies as previously described [14]. Vessels were mounted
as a ring preparation on two 40 m stainless steel wires
in an isometric Mulvany-Halpern small-vessel myograph
(J.P. Trading I/S, Aarhus, Denmark) [15]. One wire was
attached to a force transducer and the other to a microm-
eter [14, 15]. This arrangement enabled the wall tension
to be measured at a predetermined internal circumfer-
ence. Both dissection and mounting of the vessels were
carried out in cold (4C) PSS. The two segments of resis-
tance vessels from each individual were studied in paral-
lel. One was treated by the experimental protocol de-
scribed below; the other served as a time control. It was
contracted repeatedly with norepinephrine (105 mol/L).
Vessel experimental procedure
Resistance vessels were warmed in PSS to 37C, equili-
brated for 30 minutes, and the internal circumference
set to give a wall tension of 0.2 mN/mm. The myograph
chamber was bubbled with 5% CO2 and 95% O2 to main-
tain a pH of 7.4. The resting tension/internal circumfer-
ence relationship for each vessel was determined. The
internal circumference was set to 0.9  L100, where L100
is the calculated internal circumference the vessel would
have had in vivo when relaxed and under a transmural
pressure of 100 mm Hg [15]. Thereafter, the vessels were
incubated for 30 minutes in PSS, which was changed
each 10 minutes. Vessels were contracted three times
with norepinephrine (105 mol/L), followed by one expo-
sure to high-potassium solution (KPSS), where sodium
chloride was replaced by potassium chloride and finally
a repeat exposure to PSS contained norepinephrine (105
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mol/L). Contractions were maintained for 3 minutes be-
fore rinsing with PSS. Thereafter, the vessels were rinsed
three times with PSS and left to recover for 20 minutes.
For relaxation studies, vessels were precontracted with
norepinephrine (105 mol/L) and relaxed with Ach (109
to 105 mol/L). The bath was rinsed with PSS three times
and the precontracted vessels relaxed with 3-morpholli-
nosydnonimine (SIN-1) (109 to 103 mol/L). The vessels
were rinsed and incubated with l-arginine (103 mol/L)
for 30 minutes after which the norepinephrine contrac-
tion and ACh relaxation responses were repeated. Fi-
nally, the vessels were rinsed with PSS and incubated
with L-NAME (104 mol/L) for 30 minutes, after which
the norepinephrine contraction and ACh relaxation re-
sponses were repeated.
All solutions were prepared freshly 1 day before the
experiment. ACh, norepinephrine, SIN-1, and L-NAME
were purchased from Sigma Chemical Co. (St. Louis,
MO, USA). All reagents were prepared in distilled water
and diluted to the final bath concentration with PSS.
Pilot time control studies
The time control studies showed that the constriction
to norepinephrine was unchanged for the duration of the
experiment. We had shown previously that the relaxation
responses to ACh were unchanged during incubation in
PSS for 30 minutes, 60 minutes, and 120 minutes [12].
Moreover, in a further time control experiment with
subcutaneous resistance arteries from normal controls
and ADPKD patients, we found that the maximum re-
sponses to norepinephrine and the sensitivity to ACh
remained stable over a 10-hour period (data not shown).
Measurements of NOS activity of vessels
Frozen vessels were pulverized and solubilized in a
homogenization buffer containing 25 mmol/L Tris-HCl
(pH 7.4), 1 mmol/L EDTA and 1 mmol/L ethylenegly-
coltetraacetic acid (EGTA) at 4C with a tissue grinder
fitted with a motor-driven, ground-glass pestle. Homoge-
nates were centrifuged at 15,000g for 5 minutes at 4C to
remove tissue debris without precipitation of the plasma
membrane fragments [16]. The supernatant was used for
determination of NOS activity and protein mass.
NOS activity of vessels was measured with NOS De-
tectTM Assay Kit (Stratagene, Alexis Corporation, Lau-
sen, Switzerland) by the conversion of [14C]-l-arginine
to [14C]-l-citrulline (Amersham International, Piscatawa,
NJ, USA) [17, 18]. NOS activity was expressed as pico-
moles of citrulline formed per 45 minutes per milligram
of protein.
Plasma and urinary NOX assay
All subjects fasted for 12 hours overnight to reduce
diet-related nitrate production [19]. Blood samples were
heparinized and plasma separated. Urinary samples were
diluted with 2-isopropanol at a final concentration of
10% to prevent bacterial activity [20]. Plasma and uri-
nary samples were frozen at –20C until analyzed.
NOX concentration was measured in duplicate using
a nitric oxide colorometric assay kit (Griess Reaction,
Boehringer, Inc., Mannheim, Germany).
Statistics
Data are expressed as mean  SD. Statistical differ-
ences are evaluated by multiple one-way analysis of vari-
ance (ANOVA) or by Newman-Keuls statistics among
groups. ACh sensitivity is expressed as pED50, which is
the (–log) concentration of the drug required to produce
50% of the maximum response. Relaxation responses to
the ACh and SIN-1 are expressed as a percentage decline
for the maximum contractile response. The statistical
significance is defined as P 0.05. Statistica 5.0 (StatSoft,
Tulsa, OK, USA) was used as software.
RESULTS
Clinical characteristics of the subjects
The age and gender of the groups were similar (Table 1).
The ambulatory blood pressure was higher in patients
with hypertensive ADPKD without CRI and hyperten-
sive ADPKD with CRI and essential hypertension than
in controls. The [51Cr]-EDTA clearance was lower in
hypertensive ADPKD patients with CRI than in other
groups. A modestly decreased GFR of 56 mL/min was
found in one normotensive patient with ADPKD, who
had a normal serum creatinine concentration and there-
fore was included in the study.
Endothelium-dependent relaxation (EDR)
The ACh-induced maximum EDR (Emax) and pED50
were attenuated significantly in vessels from all patient
groups. The most severely impaired responses were in
vessels from patients with essential hypertension. These
defects in essential hypertension were significantly
greater than those recorded in both hypertensive groups
with ADPKD (with or without CRI), which themselves
were significantly greater than in normotensives with
ADPKD (Fig. 1) (Table 2). In individuals with normal
renal function (GFR 80 to 120 mL/min) from all four
groups (N  34), maximum relaxation rate was nega-
tively correlated with the 24-hour ambulatory mean
blood pressure (r  0.53, P  0.002) (Fig. 6).
Effects of L-arginine
Incubation of vessels with l-arginine significantly
shifted the midpoints of the ACh-dose response curve
to the left in normal subjects. However, l-arginine did
not significantly change the Emax or pED50 for ACh in
any of the patient groups with ADPKD or essential hy-
pertension (Table 2) (Fig. 2).
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Table 1. Characteristics of study groups (mean  SD)
Normal Normotensive Hypertensive Hypertensive Essential
control ADPKD ADPKD ADPKD-CRI hypertension
Number 10 9 6 5 9
Age years 3812 4310 4310 489 4610
Gender m/f 5/5 5/4 4/2 3/2 6/3
Cholesterol mg/dL 15413 15516 16015 15615 16717
Mean ambulatory blood pressure mm Hg 926 898 1107a 1128a 10911a
[51Cr]-EDTA clearance mL/min/1.73 m2 1009 8416 10110 1610a,b 909
Abbreviations are: ADPKD, autosomal-dominant polycystic kidney disease; CRI, chronic renal insufficiency; EDTA, ethylenediaminetetraacetic acid. MeanSD values.
aP  0.05 compared to normal controls; bP  0.001 compared to normotensive ADPKD
Fig. 1. Mean  SD values for acetylcholine (Ach)-induced relaxation
curves of norepinephrine-precontracted subcutaneous small arteries.
a, P  0.01 compared to normal controls; b, P  0.01 compared to
normotensive autosomal-dominant polycystic kidney disease (ADPKD);
c, P  0.01 compared to hypertensive ADPKD. CRI is chronic renal
insufficiency.
Effects of L-NAME
Incubation with L-NAME significantly attenuated (P
0.01) the maximum ACh-induced relaxation response
and shifted this to the right in resistance vessels from
normal controls (Fig. 2) (Table 2). However, L-NAME
did not abolish ACh-induced relaxation in these vessels.
Vessels from normotensive ADPKD patients had a mild
right-shifted response to L-NAME, but L-NAME did
not modify significantly the ACh responses in vessels
from any other groups of patients with ADPKD or essen-
tial hypertension.
Endothelium-independent relaxation
The SIN-1–induced relaxation responses were similar in
resistance vessels from all five groups of subjects (Fig. 3).
cNOS activity in resistance vessels
cNOS activity was decreased profoundly in vessels
from all patients with ADPKD. There was a significantly
greater reduction in the ADPKD patient groups with
hypertension compared to normotension, and a greater
reduction still in those with essential hypertension (Fig. 4).
Plasma and urinary NOX
Compared to normal controls, the plasma concentra-
tion of NOX and the rate of renal NOX excretion were
reduced in all patient groups with ADPKD and essential
hypertension, except for plasma NOX, which was ele-
vated in patients with CRI (Fig. 5).
DISCUSSION
The results confirm previous findings in the Han:SPRD
rat model of PKD and patients with ADPKD of an
impairment of ACh-induced, endothelium-dependent
relaxation of resistance vessels [11, 12]. The major new
findings of the present study are that ACh-induced relax-
ation response of resistance vessels of patients with
ADPKD is impaired even in the absence of hypertension
or CRI. However, this impairment is exaggerated in
ADPKD patients with hypertension, but there appears
to be no further impairment in hypertensive ADPKD
patients with CRI. The most profound defect in endothe-
lial dysfunction was found in patients with essential hy-
pertension. The endothelial defects in patients with
ADPKD and essential hypertension were associated
with a loss of an effect of L-NAME on the vessel’s re-
sponse to ACh and a major reduction in NOX excretion
and in cNOS activity of microdissected resistance vessels.
During L-NAME, the sensitivity and responsiveness to
ACh become similar in the groups with ADPKD or
essential hypertension to normal subjects. These results
suggest that both ADPKD and hypertension have inde-
pendent effects to impair endothelial function, and that
the effects of these conditions on endothelial function
can be ascribed primarily to reduced cNOS expression
and nitric oxide generation.
Endothelial function is impaired by dyslipidemia [21]
and normal aging [22]. Age and serum cholesterol levels
were similar between groups (Table 1), but variation
between subjects may have contributed to the response.
The profound impairment of ACh-mediated vasodilata-
tion in patients with essential hypertension confirms re-
sults in many, but not all, prior studies. Endothelial dys-
function in human hypertension has been documented
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Table 2. The maximum relaxation response (Emax) and sensitivity (pED50) to acetylcholine of subcutaneous resistance vessels
Normal Normotensive Hypertensive Hypertensive Essential
Index control ADPKD ADPKD ADPKD-CRI hypertension
Number 10 9 6 5 9
Vehicle
Emax % 859 7112a 616a,b 588a,b 5013a,b
pED50 7.150.01 6.690.03a 6.670.05a 6.640.04a,b 6.380.08a,b
l-arginine
Emax % 925c 798a 675a,b 639a,b 529a,b
pED50 7.420.02c 6.720.04a 6.700.09a 6.660.10a,b 6.430.06a,b
L-NAME
Emax % 687c 619c 638 577a 526a,b
pED50 6.410.27c 6.450.14c 6.640.17a,b 6.570.19a,b 6.400.14
Abbreviations are: ADPKD, autosomal-dominant polycystic kidney disease; CRI, chronic renal insufficiency. MeanSD values.
aP  0.01 compared to normal controls; bP  0.01 compared to normotensive ADPKD; cP  0.01 compared to vehicle
Fig. 2. Mean  SD values for the effects of
L-arginine or L-NAME on the acetylcholine
(Ach)-induced relaxation curves of norepi-
nephrine-precontracted subcutaneous small
arteries from five groups of subjects. a, P 
0.01 compared to physiologic salt solution
(PSS) alone.
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Fig. 3. Mean  SD values for 3-morphollinosydnonimine (SIN-1)-
induced relaxation response of norepinephrine-precontracted subcuta-
neous small arteries.
Fig. 4. Activity of constitutive nitric oxide synthase (cNOS) in isolated
vessels. Column A, normal controls; column B, normotensive autoso-
mal-dominant polycystic kidney disease (ADPKD); column C, hyper-
tensive ADPKD; column D, hypertensive ADPKD with chronic renal
insufficiency (CRI); and column E, essential hypertension. a, P  0.01
compared to normal controls; b, P  0.05 compared to normotensive
ADPKD; c, P  0.01 compared to hypertensive ADPKD.
in the peripheral and coronary macro- and microcircula-
tions [23–26] and in the renal circulation [23]. Endothe-
lium-independent relaxation responses to nitric oxide
donors are preserved in those prior studies [27–29] and
in our present series. The impairment of endothelium-
dependent relaxation cannot be ascribed to a decreased
ability of vascular smooth muscle to respond to nitric
oxide. All hypertensive patients were receiving antihy-
pertensive therapy. The direct effect of the drugs on
vascular function was minimized by harvesting the ves-
sels 24 hours or more after the last dose had been taken.
However, previous studies have shown that endothelial
dysfunction in hypertension is lessened by reduction in
blood pressure [30]. Therefore, the treatment that these
Fig. 5. Plasma and urinary NO2 /NO3 (NOX). Column A, normal con-
trols; column B, patients with normotensive autosomal-dominant poly-
cystic kidney disease (ADPKD); column C, hypertensive ADPKD;
column D, hypertensive ADPKD with chronic renal insufficiency (CRI);
and column E, essential hypertension. a, P 0.001 compared to normal
controls; b, P  0.05 compared to normotensive ADPKD; c, P  0.01
compared to hypertensive ADPKD.
Fig. 6. Linear correlation between acetylcholine-induced maximum re-
laxation and 24-hour mean ambulatory blood pressure (MBP). Values
are r  0.53; P  0.002.
hypertensive patients received may have masked the full
extent of their endothelial dysfunction.
In patients with primary aldosteronism or renal artery
stenosis, the ACh response can be restored by correction
of the cause of hypertension [23, 31]. This suggests that
hypertension per se may contribute to endothelial dys-
function in human subjects. In contrast, an impaired en-
dothelium-dependent vasodilatation appears to be a pri-
mary defect in ADPKD. Therefore, there should be
additive effects of hypertension and ADPKD, yet endo-
thelial function was impaired similarly in those with es-
sential hypertension and hypertensive ADPKD. This
may be a consequence of the almost complete (85%)
inhibition of eNOS activity in the vessels of patients in
these two groups (Fig. 4). Hypertension was associated
with a worsening of endothelial dysfunction in ADPKD,
although CRI did not appear to influence this further.
Since these studies were undertaken in resistance vessels,
and an inverse relationship was found between the de-
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gree of ACh-induced vasorelaxation and mean blood
pressure, it is possible that impaired endothelial function
contributes to hypertension in these patients.
Impaired endothelium-dependent vasodilatation in es-
sential hypertension is associated with impaired nitric
oxide availability [23]. The ACh response of vessels from
normal subjects was enhanced by l-arginine and was
blunted by L-NAME, indicating an important role for
nitric oxide. However, these responses were diminished
in normotensive patients with ADPKD and lost in those
with hypertension. This could represent an impairment
of nitric oxide generation, or an enhanced nitric oxide
bioinactivation by superoxide anion (O·2 ), which reacts
with nitric oxide to form peroxynitrite (ONOO) [32].
The high pO2 of the bath solution used in these studies
may have enhanced O·2 generation. We detected a pro-
found decrease in cNOS activity in vessels from all these
patients, associated with a decreased rate of NOX excre-
tion. This implies that a major cause of the impaired ACh
response of these patients was an impaired activity of vascu-
lar NOS. Indeed, the observation that the ACh-induced
relaxation response was little affected by L-NAME sug-
gests that an impaired ability to generate bioactive nitric
oxide in the vessels of these patients was the primary
cause of their endothelial dysfunction. The defect could
not be ascribed to a failure to provide adequate substrate
since it was not corrected with l-arginine. The possibility
of an additional defect due to enhanced nitric oxide bio-
inactivation by O·2 was not studied in these protocols.
The elevation of plasma NOX concentration in patients
with ADPKD and CRI likely reflects impaired NOX ex-
cretion [13].
There was a substantial vasorelaxation response to
ACh after L-NAME in the vessels from normal subjects
and all patient groups. Therefore, the vessels from the
patients retained a robust nitric oxide–independent,
ACh-induced vasodilator response. This was not investi-
gated further, but likely is mediated by an endothelium-
dependent hyperpolarizing factor [33].
Polycystin 1 is the protein that is affected in ADPKD.
It is required for the structural integrity of blood vessels
[34, 35]. A polymorphism of the eNOS gene (D298 eNOS
allele) has been associated with lower vascular NOS ac-
tivity in PKD1 patients [36]. There is a decrease in the
expression of NOS isoenzymes in the kidneys of a rat
model of polycystic disease as cyst development pro-
gresses [abstract; Wang D et al, XVth International Con-
gress of Nephrology, May 2–6, 1999, Buenos Aires, Ar-
gentina]. Induction of NOS with taxol inhibits cyst
growth in a mouse model of PKD [37]. These diverse
observations may suggest an important interaction be-
tween eNOS and polycystin 1 in ADPKD, consistent
with our finding of a profound reduction in NOS activity
in blood vessels.
CONCLUSION
Endothelial dysfunction predates hypertension and
CRI in ADPKD and therefore appears to be a primary
defect. However, the development of hypertension leads
to a major further defect in endothelial function. These
defects in ADPKD can be ascribed to defective cNOS
activity.
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